Skip to main content
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Subscribe
Home
Issues
2024
November 2024 Vol 17, Payers' Guide to FDA Updates
2023
December 2023 Vol 16, Payers' Guide to FDA Updates
September 2023 Vol 16, Payers' Guide to FDA Updates
June 2023 - Vol 16 No 1
Issue Archive
Topics
Conference Correspondent
ESMO 2024 - Small Cell Lung Cancer
EHA 2024 – Wrap-Up: Myelodysplastic Syndrome
ASCO 2024 – Wrap-Up: Myelodysplastic Syndrome
Multimedia
Videos
Interview with the Innovators
Editorial Board
About
About AHDB
Contact Us
Permissions
Editorial Policies
Editorial Process
Advertising Policy
Richard F Radzin, PharmD
Executive Consultant, CGI Federal, Cleveland, OH
Executive Consultant, CGI Federal, Cleveland, OH
Authored Items
Addressing Costs and Continuity of Care through Innovative Solutions for Infused Therapies: A Collaborative Experience with Infliximab
Rhett Johnson, MA
,
Richard F Radzin, PharmD
,
Edward N. Freeman, FACMPE, MBA
January/February 2011, Vol 4, No 1
in
Original Research
,
Practice Management
The H-E-B Value-Based Health Management Program: Impact on Asthma Medication Adherence and Healthcare Cost
Richard F Radzin, PharmD
,
Anna O. D’Souza, PhD
,
Beth Common, MBA
,
Roshan Rahnama, MPH
,
Steven Burch, PhD
,
Timothy S. Regan, BPharm, RPh
November/December 2010, Vol 3, No 6
in
Original Research
,
Practice Management
Last modified: February 10, 2015